Docetaxel News and Research RSS Feed - Docetaxel News and Research

Docetaxel is approved by the Food and Drug Administration (FDA) to be used alone or with other drugs to treat certain types of breast and non-small cell lung cancer (NSCLC). It is also approved to be used with other drugs to treat squamous cell carcinoma of the head and neck (SCCHN) and certain types of gastric and prostate cancer.

Docetaxel is a semi-synthetic, second-generation taxane derived from a compound found in the European yew tree Taxus baccata. Docetaxel displays potent and broad antineoplastic properties; it binds to and stabilizes tubulin, thereby inhibiting microtubule disassembly which results in cell- cycle arrest at the G2/M phase and cell death. This agent also inhibits pro-angiogenic factors such as vascular endothelial growth factor (VEGF) and displays immunomodulatory and pro-inflammatory properties by inducing various mediators of the inflammatory response. Docetaxel has been studied for use as a radiation-sensitizing agent.
EGFR biomarkers predict NSCLC response to vandetanib

EGFR biomarkers predict NSCLC response to vandetanib

Biomarker analyses of tumour samples from the ZODIAC study indicate that epidermal growth factor receptor gene copy number and mutation status may help identify the non-small-cell lung cancer patients most likely to benefit from treatment with vandetanib plus docetaxel. [More]
Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck reports results from global EMEND Phase 3 study for CINV prevention in pediatric cancer patients

Merck, known as MSD outside the United States and Canada, today announced results from a global, investigational Phase 3 study to evaluate the safety and efficacy of EMEND (aprepitant) in the prevention of chemotherapy-induced nausea and vomiting (CINV) in pediatric cancer patients, aged 6 months to 17 years. [More]
BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics inks research agreement with Roche to discover novel nanomedicines

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins, today announced that it has entered into a research agreement with Roche to discover novel nanomedicines using Accurins for the treatment of diseases in therapeutic areas outside of oncology. [More]
Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Protein test predicts NSCLC survival benefit for chemotherapy over erlotinib

Italian study results confirm that a multivariate serum protein test predicts improved survival after treatment with chemotherapy versus erlotinib for non-small-cell lung cancer, but only among patients who are likely to have a poor outcome with the latter treatment type. [More]
Survival differences after docetaxel, erlotinib are EGFR dependent

Survival differences after docetaxel, erlotinib are EGFR dependent

Results from the DELTA trial indicate no significant differences in progression-free or overall survival after treatment with docetaxel versus erlotinib in non-small-cell lung cancer patients unselected for their epidermal growth factor receptor mutation status. [More]
New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

New strategy prolongs survival in men with newly diagnosed, metastatic prostate cancer

Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute and the Eastern Co-operative Oncology Group. [More]
New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

New understanding of toxicity levels of chemotherapy regimens used for early stage breast cancer

Oncologists now have a new understanding of the toxicity levels of specific chemotherapy regimens used for women with early stage breast cancer, according to research from The University of Texas MD Anderson Cancer Center. [More]
Findings may help medical researchers identify effective drug targets for triple negative breast cancer

Findings may help medical researchers identify effective drug targets for triple negative breast cancer

The suppression of two genes reduce breast cancer tumor formation and metastasis by interfering with blood vessel formation and recruitment, report scientists from Houston Methodist and five other institutions in the Proceedings of the National Academy of Sciences (now online). [More]
New fluorescent molecule paves way for easier and higher quality imaging of cells

New fluorescent molecule paves way for easier and higher quality imaging of cells

Like our own bodies, cells have their own skeletons called 'cytoskeletons' and are made of proteins instead of bones. [More]
Biotech to the rescue

Biotech to the rescue

MIT professor Ram Sasisekharan's three biotech companies — Momenta Pharmaceuticals, Cerulean Pharma, and Visterra — share a similar goal. [More]

Hospira’s net sales increase 6.3% to $1.1B in first quarter 2014

Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, today reported results for the first quarter ended March 31, 2014. [More]
FDA approves Cyramza to treat patients with advanced stomach cancer

FDA approves Cyramza to treat patients with advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration (FDA) approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

FDA approves molecularly targeted drug as second-line treatment for advanced stomach cancer

Based on results of a clinical trial led by Dana-Farber Cancer Institute scientists, the U.S. Food and Drug Administration approved a molecularly targeted drug as second-line treatment in advanced stomach cancer that has progressed after standard chemotherapy has failed. [More]
Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas, Medivation submit European Marketing Authorization Application for XTANDI capsules

Astellas Pharma Inc. and Medivation Inc. today announced the submission of a variation to amend the European Marketing Authorization Application for XTANDI® (enzalutamide) capsules for the treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy and in whom chemotherapy is not yet clinically indicated. [More]
Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Tgen professor to receive 2014 Hope Funds Award for developing numerous cancer treatments

Dr. Daniel D. Von Hoff, who has been instrumental in developing numerous new cancer treatments, is among this year's recipients of the Award of Excellence from the Hope Funds for Cancer Research. [More]
BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013. [More]
CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx initiates Phase 3 clinical trial to evaluate efficacy of aldoxorubicin in STS patients

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has initiated a pivotal global Phase 3 clinical trial to evaluate the efficacy and safety of aldoxorubicin as a second-line treatment for patients with soft tissue sarcoma (STS) under a Special Protocol Assessment with the FDA. [More]

Measuring circulating tumor cells may help better predict prostate cancer survival

New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) - the cells that spread cancer through the body - may be a better predictor of patient survival than the prostate specific antigen (PSA). [More]
Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals' Hsp90 inhibitor ganetespib selected for study in I-SPY 2 TRIAL

Synta Pharmaceuticals Corp. and QuantumLeap Healthcare Collaborative today announced that Synta's lead drug candidate, the Hsp90 inhibitor ganetespib, has been selected for study in the I-SPY 2 TRIAL (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2). [More]
Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

Dr. Daniel D. Von Hoff named one of ASCO's 50 Oncology Luminaries

In association with its 50th anniversary, the American Society of Clinical Oncology has named Dr. Daniel D. Von Hoff one of ASCO's 50 Oncology Luminaries, celebrating 50 doctors who over the past half-century have significantly advanced cancer care. [More]